Best of ASCO - 2014 Annual Meeting



Attend this session at the
2017 ASCO Annual Meeting!

Session: What's Next in Immunotherapy for Head and Neck Cancer?

Type: Clinical Science Symposium

Time: Tuesday June 6, 8:00 AM to 9:30 AM

Location: S100a

Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).

Advanced Disease

Head and Neck Cancer

2017 ASCO Annual Meeting

Abstract No:

J Clin Oncol 35, 2017 (suppl; abstr 6009)

Author(s): Robert I. Haddad, Tanguy Y. Seiwert, Laura Quan Man Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph Paul Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Lingkang Huang, Mark Ayers, Robin Mogg, Razvan Cristescu, Jonathan D. Cheng, Ranee Mehra; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; University of Washington, Seattle, WA; H. Lee Moffitt Cancer Canter and Research Institute, Tampa, FL; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sheba Medical Center, Tel Hashomer, Israel; Yale Cancer Center, New Haven, CT; National Cancer Center Hospital East, Kashiwa, Japan; Seoul National University Hospital, Seoul, Republic of Korea; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Aichi Cancer Center Hospital, Aichi, Japan; Merck & Co., Inc., Kenilworth, NJ; Fox Chase Cancer Center, Philadelphia, PA

Abstract Disclosures


Background: Somatic mutational load (ML) is associated with response to anti CTLA-4 and PD-1/-L1 immunotherapies in select tumors, due to formation of neoepitopes not subject to central immune tolerance. Neoepitopes specific to HPV, EBV virus infection are also present in some HNSCC. An IFNγ gene expression profile (GEP) characteristic of tumor inflammation is also related to response to anti PD-1/-L1 therapy. This study evaluated relationships between ML and clinical outcome and independent predictive values of ML and GEP in patients with HNSCC treated with pembrolizumab. Methods: Whole exome sequencing (WES) and GEP were assessed in FFPE tumor specimens of patients with HNSCC (KEYNOTE 012; subsets of B1 [PD-L1+, n = 34] and B2 [PD-L1+/, n = 73] cohorts). ML, neoantigen load (NL), HPV/EBV status and clonality were assessed by standard WES analytical methods. GEP score is a weighted sum of normalized expression values of 18 genes. Statistical testing of ML and response, and ML and GEP relationship by HPV/EBV status was prespecified. Results: There were 73 patients identified as HPV and EBV (n = 25 in B1; n = 48 in B2). In HPV and EBV patients in B1 and B2 cohorts, respectively, associations between ML and objective response (OR) (P = 0.029 and 0.055; AUROC 0.89 and 0.63), and GEP and OR (P = 0.064 and 0.01; AUROC 0.82 and 0.74) were statistically significant. In combined cohorts of HPV and EBV patients, ML and GEP were significantly associated with OR (P = 0.009 and 0.002; AUROC 0.70 and 0.76, respectively). ML and GEP were only weakly correlated (r = 0.173). In a joint model, ML was significantly associated with response (p = 0.020) after adjusting for GEP (also significant, p = 0.006). NL and clonality weighted ML were also significantly associated with response (P = 0.026 and 0.006, respectively). In HPV+ or EBV+subjects, OR association was not significant for ML, possibly due to a dominance of viral vs somatic neoepitopes; GEP was significant, likely due to tumor inflammation. Conclusions: ML and GEP are independently predictive of response to pembrolizumab in HPV/EBV patients with HNSCC; GEP was predictive regardless of viral status. ML and GEP may have utility in characterizing responses to anti PD-1 therapies and novel cancer regimens in HNSCC. Clinical trial information: NCT01848834

Other Abstracts in this Sub-Category:


1. Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial.

Meeting: 2017 ASCO Annual Meeting Abstract No: 6000 First Author: Athanassios Argiris
Category: Head and Neck Cancer - Advanced Disease


2. A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).

Meeting: 2017 ASCO Annual Meeting Abstract No: 6002 First Author: Anthony T. C. Chan
Category: Head and Neck Cancer - Advanced Disease


3. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.

Meeting: 2017 ASCO Annual Meeting Abstract No: 6005 First Author: Ming-Yuan Chen
Category: Head and Neck Cancer - Advanced Disease